Inhalable Drugs Market 2024 - Size, Share, Outlook, Overview 2033

The new report published by The Business Research Company, titled Inhalable Drugs Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the inhalable drugs market size has grown strongly in recent years. It will grow from $33.29 billion in 2023 to $35.48 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The inhalable drugs market size is expected to see strong growth in the next few years. It will grow to $46.19 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12490&type=smp

Surge In Respiratory Diseases Propels Growth Of Inhalable Drug Market
The increasing prevalence of respiratory diseases is expected to propel the growth of the inhalable drug market going forward. Respiratory diseases are medical conditions that affect the respiratory system, which includes the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Inhalable drugs are a crucial and effective treatment option for several respiratory disorders as they deliver medication directly to the lungs. For instance, in June 2023, according to the Australian Institute of Health and Welfare, an Australia-based government agency, there were approximately 6,551 deaths or 135 deaths per 100,000 population caused by respiratory chronic conditions in Australia in 2021, representing 27.1% of all deaths. Furthermore, chronic obstructive pulmonary disease (COPD) accounted for 2.6% of underlying-cause respiratory deaths, respectively. Therefore, the increasing prevalence of respiratory diseases will drive the future inhalable drug market.

Inhalable Drug Market Evolution Pioneering Product Innovations For Enhanced Patient Outcomes
Product innovations are a key trend gaining popularity in the inhalable drug market. Major companies operating in the inhalable drug market are focused on advances in inhalable drugs to sustain their position in the market. For instance, in July 2022, DMV-Fonterra Excipients GmbH & Co. KG, a Germany-based pharma company, expanded its dry powder inhalation (DPI) portfolio with the launch of Lactohale 400. This new grade can be customized to meet specific pharmaceutical company needs and developed jointly with formulators to ensure patient outcomes. The extensive spectrum of lactose-based additives is intended to provide appropriate characteristics for various inhaled therapies. Lactohale 400 is a crushed, dry lactose type suited to DPI applications requiring high flow and cohesiveness. Its anhydrous nature sets it apart from commonly used lactose carriers and offers a different aerosolization performance than lactose monohydrate with the same particle size.

The inhalable drugs market covered in this report is segmented -

1) By Product: Aerosol, Dry Powder Formulation, Spray
2) By Distribution Channel: Hospital Pharmacy, Pharmacy Stores, Other Distribution Channels
3) By Application: Respiratory Diseases, Non-Respiratory Diseases
4) By End Users: Adults, Pediatric, Geriatric

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12490&type=discount

Major companies operating in the inhalable drugs market report are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH,Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Mylan N.V., Catalent Inc., Sumitomo Pharma Co. Ltd., Intertek Group plc, AptarGroup Inc., Cipla Inc., Glenmark Pharmaceuticals Inc., Piramal Pharma Ltd., Zambon S.p.A., Sunovion Pharmaceuticals Inc., Nelson Laboratories LLC, Vectura Group Limited, Abiogen Pharma, Quotient Sciences, AeroGen Pharma, CareFusion Corporation, Alaxia S.A.S., Pharmaxis Ltd., Avalyn Pharma Inc., TFF Pharmaceuticals Inc.

Contents of the report:
1. Executive Summary
2. Inhalable Drugs Market Report Structure
3. Inhalable Drugs Market Trends And Strategies
4. Inhalable Drugs Market - Macro Economic Scenario
5. Inhalable Drugs Market Size And Growth
…..
27. Inhalable Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/inhalable-drugs-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.